DISIPAL
LOE Approachingorphenadrine hydrochloride
NDAORALTABLET
Approved
May 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DISIPAL (orphenadrine hydrochloride) is an oral anticholinergic agent approved in 1957 for treatment of muscle spasms and movement disorders. It works by blocking acetylcholine receptors in the central and peripheral nervous system to reduce muscle rigidity and tremor. This legacy small-molecule therapeutic is now in lifecycle decline with loss of exclusivity approaching.
LOE Approaching
Minimal commercial momentum; small, defensive team focused on retention rather than growth as generic competition intensifies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DISIPAL offers minimal growth opportunity and zero linked jobs in the current market. This role is suited for professionals seeking stable, lower-intensity work managing a legacy product through decline, or for those building expertise in generic competition strategy and specialty market dynamics.
Senior Brand Manager (Specialty/Legacy)Medical Science Liaison (Maintenance)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.